Eric Lefkofsky Jumps Ahead With Tempus

Eric Lefkofsky is seeking to bring the medical industry into a whole new level of profitability with the use of big data. So far, over half a billion dollars has been raised to analyse information from cancer patients, in order to understand more about their biology. In the future, it’s expected that Eric Lefkofsky’s company, named Tempus, will reach over $3 billion in value. Tempus uses cutting-edge technology to analyse samples taken from cancer patients. Some of this technology includes a genomic sequencer that is priced at around $1 million. Much faith is being put into the idea that more data on patients will allow medical professionals to perform their job more efficiently. The investments that have gone in to connecting doctors with patient data has given entrepreneurs an opportunity to woo the market with ideations of an interconnected future in medicine. An issue that Tempus faces is the overall cost of conducting analysis of Cancer samples. These operations can cost up to $5,000 for every analysis. Eric Lefkofsky believes that the initial financial strain of this business will be worth the pay-off. The quest for data has led Tempus to reach a licencing deal with the American Society of Clinical Oncology to organize a chunk of their data. Along with this trove of information, there is also the fact that many oncologists in the United States send their patient information to Tempus as well. This all supports the increasing network of information that Tempus enjoys in order to sell its data to researchers medical corporations. Lefkofsky is also co-founder of Groupon, yet Tempus is the business that has brought him the most pride and pleasure. Perhaps a solid reason that Lefkofsky has entered this field is due to the fact that in 2014 his wife was diagnosed with breast cancer. He was startled by how little data there was to aid his wife, who is still striving to make it through each day living with the disease. There are some competitors that work in the same industry, however Tempus is one of the most creative and well-funded players in the medical data market. Read more about Eric Lefkofsky: https://www.americaninno.com/chicago/funding-chicago/cancer-fighting-startup-tempus-raises-80m-in-new-funding/